Quantcast

argenx raises approximately $100 million gross proceeds

argenx, a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, announced today the pricing of its initial public offering in the United States with anticipated gross proceeds totalling approximately $100 million from the sale of 5,865,000 American Depository Shares (“ADSs”), at a price to the public of $17.00 per ADS.

All of the ADSs are being offered by argenx and each of the ADSs offered represents the right to receive one ordinary share.

argenx had earlier increased the Offering from 3.6 million ADSs to 5.0 million ADSs and has finally further increased the Offering to approximately 5.9 million ADSs.

 

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.